Anavex Life Sciences Corp (AVXL)

[Talon38]

Biostock.....Excellent thoughts to mull over the weekend. Only Biogen has had 2-73 in their lab and they are iminately aware of Dr Lasik's (WSU) work that points towards 2-73's possible ability to remyelinate in the case of MS. I speculate the whole turndown in the MTA was about the Alzheimer's factor of 2-73 and Aducanumab. With the squeeze on Biogen's MS drugs Tecfidera and Tysabri and the 2-73's remyelination capabilities, it doesn't leave Vounatsos much choice since 70% of Biogen's revenue comes from MS.

So, your analysis has sound logic and the first week in June is a critical time point for the FDA/Biogen/Anavex.

From a previous post: Take a look again at the link that puts "myelin" in the picture for the CNS.

More on the "Myelin" aspect of brain health

----

https://www.biospace.com/article/new-insight-into-what-causes-of-multiple-sclerosis/?utm_campaign=GenePool&utm_source=hs_email&utm_medium=email&utm_content=77807406&_hsenc=p2ANqtz-_hiAj0jq97sXVSucsmrg5lPACHUYIs4MaAqvyDsHK6RQAW4gxJi6AVPjOhKgfXldgyR14j2LW03lfYgv5iN_JmWDSqyg&_hsmi=77807406

----

Oral Presentation Details:
Session: Remyelination: from biology to clinical trials
Title: Sigma 1 receptor agonists as potential protective and reparative therapy in multiple sclerosis
Date: October 27, 2017
Time: 2:52 pm ECT
Location: Hall B, Le Palais des Congrès de Paris
2 Place de la Porte Maillot
75017 Paris, France
“A unique feature of ANAVEX2-73, compared to another sigma-1 receptor agonist we studied, is that ANAVEX2-73 accelerates the maturation of oligodendrocyte precursor cells (OPC) to oligodendrocytes (OL),” said Dr Robert P. Lisak. “This is an important feature since OPCs can replace lost OLs by maturing into new potential myelin-producing cells. In other words, ANAVEX2-73 might promote remyelination. Further data also demonstrates that ANAVEX2-73 provides protection for OL, OPCs, as well as central nervous system neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.“

“These findings provide additional evidence for the neuroprotective and neurorestorative effects of ANAVEX2-73, as well as further validating the mechanism of our target,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.